Fig. 7. Gilteritinib in combination with 25HC regresses tumors.

A549 cells were subcutaneously injected into mice. When the average tumor volume reached 100 mm³, mice were randomized to four treatment groups (vehicle control, 5 mg/kg gilteritinib, 30 mg/kg 25HC, gilteritinib plus 25HC). All mice were administrated via oral gavage once daily for a continuous 14 days, and tumor volumes were measured every 2 days. A Tumor growth curves. B Images of the excised tumors. C After treatment, tumor weight was measured. D Tumor sections were subjected to immunohistochemistry, and then representative images of the tumor sections stained with PCNA are shown. E Mouse body weight was measured every 2 days. F Representative images of liver tissues stained with Hematoxylin-eosin (H&E) are shown. **P < 0.01, ***P < 0.001.